Tolaney S, et al. MonarcHER: a randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of care chemotherapy in women with HR+, HER2+ advanced breast cancer. Abstract LBA23. ESMO Congress 2019, 29 sept. Barcelona, Spanje.
Gepersonaliseerde autologe neoantigeenspecifieke T-celtherapie bij gemetastaseerd melanoom
mrt 2025 | Dermato-oncologie, Immuuntherapie